Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idec Zevalin May Need Central Monitoring Of Bio-Images, FDA Cmte. Suggests

Executive Summary

Idec should establish a centralized monitoring program to assess Zevalin biodistribution images, FDA Oncologic Drugs Advisory Committee Chair Stacy Nerenstone, MD, Helen & Harry Gray Cancer Center, suggested during the Sept. 11 review of the radioimmunotherapy.

You may also be interested in...



Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica

The delay in FDA approval of Idec's non-Hodgkin's lymphoma treatment Zevalin could also cause a delay in finalizing Medicare reimbursement for the product

Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica

The delay in FDA approval of Idec's non-Hodgkin's lymphoma treatment Zevalin could also cause a delay in finalizing Medicare reimbursement for the product

Idec, GSK, Corixa Discussing Licensing Of Radioimmunotherapy Patents

Idec is considering licensing patents from Corixa that may cover its radioimmunotherapy Zevalin.

Related Content

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel